Quadrature Capital’s DNA X Inc SONM Stock Holding History

Quadrature Capital’s Portfolio SONM Stock Details SONM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-675	Closed	-$112K	–	967
2021 Q4	$112K	Buy	+675	New	+$205K	0.01%	616

Other funds holding SONM

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $5.32B AUM 30.24% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Quadrature Capital's SONM Position: Q1 2022 in Review

Quadrature Capital sold out of DNA X Inc (SONM) in Q1 2022, closing a stake of 675 shares — an estimated $112K sold.

Quadrature Capital first reported a position in SONM in Q4 2021 and held it in 1 quarter. The position peaked at $112K in Q4 2021. 13 funds tracked by Wall St. Rank hold SONM as of Q1 2022.

Quadrature Capital reported no remaining DNA X Inc position as of Q1 2022 after selling out during the quarter.
Quadrature Capital sold 675 DNA X Inc shares in Q1 2022, an estimated $112K.
Quadrature Capital first reported a position in DNA X Inc in Q4 2021 and held it in 1 quarter.
Quadrature Capital's DNA X Inc position peaked at $112K in Q4 2021.
13 funds tracked by Wall St. Rank held DNA X Inc as of Q1 2022.

Based on Quadrature Capital's 13F filing for Q1 2022, filed 16 May 2022.